Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma 1Rectal Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Neuroblastoma 1Hepatoblastoma 1Head and Neck Neoplasms 1HER2 Positive Advanced Gastric Cancer 1Basal Cell Carcinoma of the Head and Neck 1

Interventions

pembrolizumab 160Carboplatin 143Paclitaxel 125Cyclophosphamide 93130-nm albumin-bound paclitaxel 66Capecitabine 63Gemcitabine 54Doxorubicin 49Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 40Cisplatin 37Nivolumab 34sacituzumab govitecan 32olaparib 32Epirubicin 32Docetaxel 28eribulin 27Specimen Handling 26Bevacizumab 26durvalumab 25camrelizumab 23Drug Therapy 22Biopsy 22Magnetic Resonance Spectroscopy 21toripalimab 18Radiotherapy 17spartalizumab 16Everolimus 15fludarabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Triple Negative Breast Neoplasms × Tissue Banks × Clear all
NCT06635980 2025-12-12

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

Mayo Clinic

Phase 2 Recruiting
120 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡